Golimumab in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series and Review of the Literature

CONCLUSION: In our experience, golimumab has been shown to be a safe and effective therapy for CRMO and demonstrated improvement in paradoxical psoriasis in many patients. Longer follow-up periods would be helpful to develop longer term outcomes data for patients with CRMO and overall paradoxical psoriasis risk.PMID:37479948 | DOI:10.1007/s40272-023-00581-y

Source: Paediatric Drugs - July 21, 2023 Category: Pediatrics Authors: Claire Yang Natalie Rosenwasser Xing Wang Zheng Xu Joshua Scheck Markus D Boos Deepti Gupta Heather A Brandling-Bennet Robert Sidbury Ramesh S Iyer Yongdong Zhao Source Type: research